Steroid eye drops

DRUG3 trials

Sponsors

AbbVie, Radboud University Medical Center, Sohag University

Conditions

Chronic Central Serous ChorioretinopathyGlioblastoma MultiformeVernal Keratoconjunctivitis

Phase 3

UNITE Study: Understanding New Interventions With GBM ThErapy

TerminatedNCT03419403

AbbVieGlioblastoma Multiforme

Start: 2018-07-30End: 2020-03-03Updated: 2021-04-14

Steroid Eye Drops in Chronic Central Serous Chorioretinopathy

RecruitingNCT05633576

Radboud University Medical CenterChronic Central Serous Chorioretinopathy

Start: 2023-02-19End: 2025-07-19Target: 40Updated: 2024-04-11

Unknown Phase

Tacrolimus Eye Drops in Treatment of Vernal Keratoconjunctivitis

Not yet recruitingNCT07138742

Sohag UniversityVernal Keratoconjunctivitis

Start: 2025-09-30End: 2027-09-30Target: 90Updated: 2025-08-24

Related Papers

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

Ophthalmic Research2023-01-014 citations

ACTR-21. MANAGEMENT OF OCULAR SIDE EFFECTS IN PATIENTS WITH EGFR-AMPLIFIED GLIOBLASTOMA RECEIVING DEPATUXIZUMAB MAFODOTIN

Neuro-Oncology2018-11-01